InflaRx Investor Relations Material
Latest events
Investor Update
InflaRx
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from InflaRx N.V.
Access all reports
InflaRx N.V. is a clinical-stage biopharmaceutical company engaged in the discovery and development of drugs that inhibit the activation of the complement system, particularly targeting the C5a component, a potent inflammatory mediator. This focus addresses various autoimmune and other inflammatory diseases. The company's leading product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody with multiple clinical applications, including for diseases like hidradenitis suppurativa and cutaneous squamous cell carcinoma. The company is headquartered in Jena, Germany, and its shares are listed on the NASDAQ.
Key slides for InflaRx N.V.
Investor Update
InflaRx N.V.
Investor Update
InflaRx N.V.
Latest articles
The Brunello Cucinelli Story: Combining Elegance and Ethics
Explore the success of Brunello Cucinelli's unique blend of luxury craftsmanship and ethical business.
14 May 2024
Amazon's Most Notable Acquisitions Since Inception
Explore Amazon's most impactful acquisitions, from IMDb and Zappos to Whole Foods and MGM, and how these have diversified its business.
13 May 2024
Adidas vs Puma: The Story of the Dassler Brothers
An in-depth article outlining the story of the Dassler brothers, their feud with one another, and the history of Puma and Adidas.
10 May 2024
Ticker symbol
Country
🇺🇸 United States